Aurinia Pharmaceuticals Inc (AUPH)vsJohnson & Johnson (JNJ)
AUPH
Aurinia Pharmaceuticals Inc
$16.21
0.00%
HEALTHCARE · Cap: $2.17B
JNJ
Johnson & Johnson
$283.62
+1.11%
HEALTHCARE · Cap: $657.68B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 30774% more annual revenue ($99.33B vs $321.74M). AUPH leads profitability with a 97.7% profit margin vs 16.2%. AUPH trades at a lower P/E of 7.1x. AUPH earns a higher WallStSmart Score of 59/100 (C).
AUPH
Buy59
out of 100
Grade: C
JNJ
Buy54
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 53 in profit
Keeps 98 of every $100 in revenue as profit
Strong operational efficiency at 51.6%
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 25.7%
Generating 6.4B in free cash flow
Areas to Watch
0.0% earnings growth
Trading at 8.4x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AUPH
The strongest argument for AUPH centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 97.7% and operating margin at 51.6%. Revenue growth of 13.9% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.7%.
Bear Case : AUPH
The primary concerns for AUPH are EPS Growth.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 41.5x leaves little room for execution misses.
Key Dynamics to Monitor
AUPH carries more volatility with a beta of 1.34 — expect wider price swings.
AUPH is growing revenue faster at 13.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AUPH scores higher overall (59/100 vs 54/100), backed by strong 97.7% margins and 13.9% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aurinia Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?